DDInter1662 DDInter1925
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.[A1846,A187075,T28]
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Sertraline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Sertraline {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Sertraline {u} (Compound) upregulates {v} (Gene) MSMO1
MSMO1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Sertraline {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Sertraline {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Sertraline {u} (Compound) resembles {v} (Compound) Maprotiline
Maprotiline {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Sertraline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Sertraline {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) regulates {v} (Gene) IKZF1
IKZF1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Sertraline {u} (Compound) upregulates {v} (Gene) MAL
MAL {u} (Gene) is regulated by {v} (Gene) PAN2
PAN2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Sertraline {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is regulated by {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vemurafenib
Sertraline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Sertraline (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Vemurafenib (Compound)
Sertraline (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is downregulated by Vemurafenib (Compound)
Sertraline (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Vemurafenib (Compound)
Sertraline (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Sertraline (Compound) resembles Maprotiline (Compound) and Maprotiline may lead to a major life threatening interaction when taken with Vemurafenib
Sertraline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Sertraline (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) regulates IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Vemurafenib (Compound)
Sertraline (Compound) upregulates MAL (Gene) and MAL (Gene) is regulated by PAN2 (Gene) and PAN2 (Gene) is upregulated by Vemurafenib (Compound)
Sertraline (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is regulated by ALB (Gene) and ALB (Gene) is bound by Vemurafenib (Compound)